Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other neoplasm 1

Conditions

Breast Neoplasms 1225Neoplasms 1042Carcinoma, Non-Small-Cell Lung 751Prostatic Neoplasms 689Colorectal Neoplasms 591Lung Neoplasms 574Pancreatic Neoplasms 404Leukemia, Myeloid, Acute 396Neoplasm Metastasis 386Multiple Myeloma 372Ovarian Neoplasms 371Stomach Neoplasms 319Carcinoma, Hepatocellular 301Recurrence 281Melanoma 280Brain Neoplasms 280Squamous Cell Carcinoma of Head and Neck 268Head and Neck Neoplasms 235Glioblastoma 233Endometrial Neoplasms 232Triple Negative Breast Neoplasms 229Precursor Cell Lymphoblastic Leukemia-Lymphoma 228Lymphoma 225Uterine Cervical Neoplasms 223Sarcoma 200Hematologic Neoplasms 199Urinary Bladder Neoplasms 197Esophageal Neoplasms 193Carcinoma, Renal Cell 189Lymphoma, Non-Hodgkin 176

Interventions

thymoglobulin 1fludarabine phosphate 1fludarabine 1Whole-Body Irradiation 1Stem Cell Transplantation 1Sirolimus 1Mycophenolic Acid 1Hematopoietic Stem Cell Transplantation 1Cyclophosphamide 1Antilymphocyte Serum 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Non-Malignant Neoplasm × 1 year × Clear all
NCT04083183 2025-12-18

Total Body Irradiation and Astatine-211-Labeled BC8-B10 Monoclonal Antibody for the Treatment of Nonmalignant Diseases

Fred Hutchinson Cancer Center

Phase 1/2 Recruiting
40 enrolled
Other neoplasm

Non-Malignant Neoplasm

Data powered by HemOnc (CC BY 4.0) Colophon âš¡